Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli

Molecular and Cellular Endocrinology

Volumn 399, Issue , 2015, Pages 208-218

  Ito, Nobuaki ^a   Wijenayaka, Asiri R ^a   Prideaux, Matthew ^a   Kogawa, Masakazu ^a   Ormsby, Renee T ^a   Evdokiou, Andreas ^b   Bonewald, Lynda F ^c   Findlay, David M ^a   Atkins, Gerald J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF DENTISTRY   (United States)

Author keywords

FGF23; IL 1; LPS; Pro inflammatory cytokines; TNF; TWEAK

Indexed keywords

APOPTOSIS INDUCING FACTOR; BACTERIUM LIPOPOLYSACCHARIDE; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; FURIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; DMP1 PROTEIN, HUMAN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; FIBROBLAST GROWTH FACTOR; IL1B PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; LIPOPOLYSACCHARIDE; PHEX PROTEIN, HUMAN; PHOSPHODIESTERASE; PHOSPHOPROTEIN; SCLEROPROTEIN; TNF PROTEIN, HUMAN; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; MOUSE; NONHUMAN; OSTEOCYTE; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN PROCESSING; SEPSIS; SIGNAL TRANSDUCTION; UPREGULATION; CELL DIFFERENTIATION; CELL LINE; CHEMICALLY INDUCED; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

BONE AND BONES; CELL DIFFERENTIATION; CELL LINE; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; OSTEOCYTES; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHOPROTEINS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84908565099     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.10.007     Document Type: Article

References (49)

1. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res 2011, 26:1425-1436.
2. Barak V., Schwartz A., Kalickman I., Nisman B., Gurman G., Shoenfeld Y. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am. J. Med 1998, 104:40-47.
3. Bhattacharyya N., Wiench M., Dumitrescu C., Connolly B.M., Bugge T.H., Patel H.V., et al. Mechanism of FGF23 processing in fibrous dysplasia. J. Bone Miner. Res 2012, 27:1132-1141.
4. Brown W.W., Juppner H., Langman C.B., Price H., Farrow E.G., White K.E., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J. Clin. Endocrinol. Metab 2009, 94:17-20.
5. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res 2006, 21:1187-1196.
6. Chen I.P., Wang L., Jiang X., Aguila H.L., Reichenberger E.J. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum. Mol. Genet 2011, 20:948-961.
7. Chesney P.J., Davis J.P., Purdy W.K., Wand P.J., Chesney R.W. Clinical manifestations of toxic shock syndrome. JAMA 1981, 246:741-748.
8. Consortium T.A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet 2000, 26:345-348.
9. El-Hodhod M.A., Hamdy A.M., Abbas A.A., Moftah S.G., Ramadan A.A. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol 2012, 12:44.
10. Elisaf M., Theodorou J., Pappas H., Siamopoulos K.C. Acid-base and electrolyte abnormalities in febrile patients with bacteraemia. Eur. J. Med 1993, 2:404-407.
11. Farrow E.G., Yu X., Summers L.J., Davis S.I., Fleet J.C., Allen M.R., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E1146-E1155.
12. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet 2006, 38:1310-1315.
13. Ferrari S.L., Bonjour J.P., Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab 2005, 90:1519-1524.
14. Fukumoto S., Yamashita T. FGF23 is a hormone-regulating phosphate metabolism - unique biological characteristics of FGF23. Bone 2007, 40:1190-1195.
15. Imel E.A., Peacock M., Gray A.K., Padgett L.R., Hui S.L., Econs M.J. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab 2011, 96:3541-3549.
16. Ito N., Findlay D.M., Anderson P.H., Bonewald L.F., Atkins G.J. Extracellular phosphate modulates the effect of 1alpha,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J. Steroid Biochem. Mol. Biol 2013, 136:183-186.
17. Ito N., Findlay D.M., Atkins G.J. Osteocyte communication with the kidney via the production of FGF23: remote control of phosphate homeostasis. Clin. Rev. Bone Miner. Metab 2014, 12:44-58.
18. Jakubowski A., Browning B., Lukashev M., Sizing I., Thompson J.S., Benjamin C.D., et al. Dual role for TWEAK in angiogenic regulation. J. Cell Sci 2002, 115:267-274.
19. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10:4025-4031.
20. Kogawa M., Wijenayaka A.R., Ormsby R., Thomas G.P., Anderson P.H., Bonewald L.F., et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J. Bone Miner. Res 2013, 28:2436-2448.
21. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol 2005, 289:G1036-G1042.
22. Levy-Litan V., Hershkovitz E., Avizov L., Leventhal N., Bercovich D., Chalifa-Caspi V., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am. J. Hum. Genet 2010, 86:273-278.
23. Lindberg I., Pang H.W., Stains J.P., Clark D., Yang A.J., Bonewald L., et al. FGF23 is endogenously phosphorylated in bone cells. J. Bone Miner. Res 2014, in press.
24. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet 2006, 38:1248-1250.
25. Lorenz-Depiereux B., Schnabel D., Tiosano D., Hausler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am. J. Hum. Genet 2010, 86:267-272.
26. Martin A., Liu S., David V., Li H., Karydis A., Feng J.Q., et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 2011, 25:2551-2562.
27. Mendoza J.M., Isakova T., Ricardo A.C., Xie H., Navaneethan S.D., Anderson A.H., et al. Fibroblast growth factor 23 and inflammation in CKD. Clin. J. Am. Soc. Nephrol 2012.
28. Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med 1996, 184:1397-1411.
29. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146:5358-5364.
30. Rafaelsen S.H., Raeder H., Fagerheim A.K., Knappskog P., Carpenter T.O., Johansson S., et al. Exome sequencing reveals FAM20c mutations associated with FGF23-related hypophosphatemia, dental anomalies and ectopic calcification. J. Bone Miner. Res 2013.
31. Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:639-643.
32. Riedler G.F., Scheitlin W.A. Hypophosphataemia in septicaemia: higher incidence in gram-negative than in gram-positive infections. Br. Med. J. 1969, 1:753-756.
33. Rowe P.S. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell Biochem. Funct 2012, 30:355-375.
34. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem 2005, 280:2543-2549.
35. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143:3179-3182.
36. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res 2004, 19:429-435.
37. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest 2004, 113:561-568.
38. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol 2002, 3:753-766.
39. Uno J.K., Kolek O.I., Hines E.R., Xu H., Timmermann B.N., Kiela P.R., et al. The role of tumor necrosis factor alpha in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology 2006, 131:497-509.
40. Vaure C., Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front. Immunol 2014, 5:316.
41. Wang X., Wang S., Li C., Gao T., Liu Y., Rangiani A., et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 2012, 8:e1002708.
42. White K.E., Cabral J.M., Davis S.I., Fishburn T., Evans W.E., Ichikawa S., et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am. J. Hum. Genet 2005, 76:361-367.
43. Wohrle S., Bonny O., Beluch N., Gaulis S., Stamm C., Scheibler M., et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J. Bone Miner. Res 2011, 26:2486-2497.
44. Woo S.M., Rosser J., Dusevich V., Kalajzic I., Bonewald L.F. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J. Bone Miner. Res 2011, 26:2634-2646.
45. Wu A.L., Feng B., Chen M.Z., Kolumam G., Zavala-Solorio J., Wyatt S.K., et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS ONE 2013, 8:e57322.
46. Yamamoto R., Minamizaki T., Yoshiko Y., Yoshioka H., Tanne K., Aubin J.E., et al. 1alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro. J. Endocrinol 2010, 206:279-286.
47. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab 2002, 87:4957-4960.
48. Yamazawa K., Kodo K., Maeda J., Omori S., Hida M., Mori T., et al. Hyponatremia, hypophosphatemia, and hypouricemia in a girl with macrophage activation syndrome. Pediatrics 2006, 118:2557-2560.
49. Yu X., Sabbagh Y., Davis S.I., Demay M.B., White K.E. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005, 36:971-977.